Lilly appeals retatrutide classification ruling in case that could impact compounders

Alexis Kramer / endpoints - Eli Lilly is challenging a decision over how the FDA classified its experimental, next-gen obesity shot, in a case that could affect the ability of compounders to rival it. On Thursday, Lilly filed a notice ...

AI Summary: Eli Lilly is contesting a regulatory classification decision for its next‑generation obesity shot while simultaneously stockpiling doses ahead of potential U.S. approval. The dispute has broader implications for compounding pharmacies and has coincided with lawsuits accusing telehealth vendors and compounders of selling unapproved oral GLP‑1 alternatives — a messy intersection of commerce, regulation and patient safety.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

GLP‑1 drugs associated with lower addiction risk in large study / 2 months

FDA Removes Suicide Warnings from GLP‑1 Drugs / 4 months

Novo Nordisk Seeks FDA Nod for Higher‐Dose Wegovy / 6 months

Lilly’s Zepbound bests Novo’s CagriSema in head‑to‑head obesity trial / 3 months

JP Morgan Healthcare Conference 2026: Pharma, AI, and Innovation Highlights / 4 months

Novo Nordisk oral GLP‑1 pill clears FDA for obesity treatment / 5 months

‘Healthy’ labels may hide a sugar bomb / 5 months